Search

Your search keyword '"van den Berg, H Marijke"' showing total 27 results
Start Over Author "van den Berg, H Marijke" Database OAIster
27 results on '"van den Berg, H Marijke"'

1. Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort

Author

Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Cardiovasculaire Epi Team 1, Fischer, Kathelijn, Carcao, Manuel, Male, Christoph, Ranta, Susanna, Pergantou, Helen, Kenet, Gili, Kartal-Kaess, Mutlu, Königs, Christoph, Carvalho, Manuela, Alvarez, Maria Teresa, Brakenhoff, Timo, Chambost, Hervé, van den Berg, H. Marijke, Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Cardiovasculaire Epi Team 1, Fischer, Kathelijn, Carcao, Manuel, Male, Christoph, Ranta, Susanna, Pergantou, Helen, Kenet, Gili, Kartal-Kaess, Mutlu, Königs, Christoph, Carvalho, Manuela, Alvarez, Maria Teresa, Brakenhoff, Timo, Chambost, Hervé, and van den Berg, H. Marijke

Published
2023

2. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: A PedNet study

Author

Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Male, Christoph, Andersson, Nadine G., Rafowicz, Anne, Liesner, Ri, Kurnik, Karin, Fischer, Kathelijn, Platokouki, Helen, Santagostino, Elena, Chambost, Hervé, Nolan, Beatrice, Königs, Christoph, Kenet, Gili, Ljung, Rolf, Van Den Berg, H. Marijke, PedNet Study Group, Poli Van Creveldkliniek Medisch, Child Health, Circulatory Health, Male, Christoph, Andersson, Nadine G., Rafowicz, Anne, Liesner, Ri, Kurnik, Karin, Fischer, Kathelijn, Platokouki, Helen, Santagostino, Elena, Chambost, Hervé, Nolan, Beatrice, Königs, Christoph, Kenet, Gili, Ljung, Rolf, Van Den Berg, H. Marijke, and PedNet Study Group

Published
2021

3. Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry-based study

Author

CTM & Statistical consultation, Directie Raad van Bestuur, Circulatory Health, Cardiovasculaire Epi Team 1, Jonker, Carla J, Oude Rengerink, Katrien, Hoes, Arno W, Mol, Peter G M, van den Berg, H Marijke, CTM & Statistical consultation, Directie Raad van Bestuur, Circulatory Health, Cardiovasculaire Epi Team 1, Jonker, Carla J, Oude Rengerink, Katrien, Hoes, Arno W, Mol, Peter G M, and van den Berg, H Marijke

Published
2020

7. Drug Registries and Approval of Drugs: Promises, Placebo, or a Real Success?

Author

Datamanagement 1, Epidemiology & Health Economics, General Practice & Nursing Science, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jonker, Carla J., Kwa, Marcel S.G., van den Berg, H. Marijke, Hoes, Arno W., Mol, Peter G.M., Datamanagement 1, Epidemiology & Health Economics, General Practice & Nursing Science, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jonker, Carla J., Kwa, Marcel S.G., van den Berg, H. Marijke, Hoes, Arno W., and Mol, Peter G.M.

Published
2018

8. Registries supporting new drug applications

Author

Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G M, Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., and Mol, Peter G M

Published
2017

9. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Author

Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group, Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, and European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group

Published
2017

10. Registries supporting new drug applications

Author

Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G M, Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., and Mol, Peter G M

Published
2017

11. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Author

Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group, Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, and European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group

Published
2017

12. Registries supporting new drug applications

Author

Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G M, Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., and Mol, Peter G M

Published
2017

13. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Author

Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group, Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, and European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group

Published
2017

14. Registries supporting new drug applications

Author

Datamanagement 1, Epidemiology & Health Economics, General Practice & Nursing Science, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G M, Datamanagement 1, Epidemiology & Health Economics, General Practice & Nursing Science, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., and Mol, Peter G M

Published
2017

15. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Author

Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Poli Van Creveldkliniek Medisch, Child Health, Datamanagement 1, Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group, Cardiovasculaire Epi Team 1, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Poli Van Creveldkliniek Medisch, Child Health, Datamanagement 1, Mancuso, Maria Elisa, Fischer, Kathelijn, Santagostino, Elena, Oldenburg, Johannes, Platokouki, Helen, Königs, Cristoph, Escuriola-Ettingshausen, Carmen, Rivard, George E, Cid-Haro, Ana Rosa, Carcao, Manuel, Ljung, Rolf, Petrini, Pia, Altisent, Carmen, Kenet, Gili, Liesner, Raina, Kurnik, Karin, Auerswald, Günther, Chambost, Hérvè, Mäkipernaa, Anne, Molinari, Angelo Claudio, Williams, Mike, van den Berg, H Marijke, and European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group

Published
2017

17. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Author

van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, Santagostino, Elena, van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, and Santagostino, Elena

Published
2016

18. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Author

van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, Santagostino, Elena, van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, and Santagostino, Elena

Published
2016

19. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Author

van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, Santagostino, Elena, van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, and Santagostino, Elena

Published
2016

21. Different impact of factor VIII products on inhibitor development?

Author

Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, van den Berg, H Marijke, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Circulatory Health, and van den Berg, H Marijke

Published
2016

22. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Author

Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Poli Van Creveldkliniek Medisch, Circulatory Health, van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, Santagostino, Elena, Cardiovasculaire Epi Team 1, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Poli Van Creveldkliniek Medisch, Circulatory Health, van den Berg, H. Marijke, Hashemi, S. Mojtaba, Fischer, Kathelijn, Petrini, Pia, Ljung, Rolf, Rafowicz, Anne, Carcao, Manuel, Auerswald, Günter, Kurnik, Karin, Kenet, Gili, and Santagostino, Elena

Published
2016

26. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Astermark, Jan, Rocino, Angiola, Von Depka, Mario, Van Den Berg, H Marijke, Gringeri, Alessandro, Mantovani, Lorenzo G, Morado, Marta, Garrido, Rosario Pérez, Schiavoni, Mario, Villar, Anna, Windyga, Jerzy, European Haemophilia Therapy Standardi-sation Board [EHTSB], Hermans, Cédric, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Astermark, Jan, Rocino, Angiola, Von Depka, Mario, Van Den Berg, H Marijke, Gringeri, Alessandro, Mantovani, Lorenzo G, Morado, Marta, Garrido, Rosario Pérez, Schiavoni, Mario, Villar, Anna, Windyga, Jerzy, European Haemophilia Therapy Standardi-sation Board [EHTSB], and Hermans, Cédric

Abstract

The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor by immune tolerance induction therapy (ITI). However, ITI procedures fail in a substantial number of patients and in many countries ITI is not even offered owing to its high cost. How patients with inhibitors are managed in different European countries is evaluated with a special focus on the use of by-passing agents, i.e. recombinant FVIIa (rFVIIa) and activated prothrombin complex concentrates (aPCC), as well as the type of monitoring performed. Investigators from 22 large haemophilia centres participating within the network of the European Haemophilia Therapy Standardisation Board (EHTSB) were asked to complete a questionnaire. rFVIIa was routinely used in all centres for both children and adults at dosages ranging from 90 to 250 mug kg(-1) at an interval of 2-4 h. aPCC was used in 85% of the centres in adults and in 25% of the centres in children with haemophilia A at dosages of 50-100 IU kg(-1) every 6-12 h. The corresponding figures for children and adults with haemophilia B were 40% and 15% of the centres, respectively. Higher dosages of both agents were considered in the case of life-threatening bleeds. General recommendations were developed, based on the information provided by the survey. The results clearly indicate the need for well-designed comparative studies to optimize the use of by-passing agents.

Published
2007

27. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Astermark, Jan, Morado, Martha, Rocino, Angiola, van den Berg, H Marijke, von Depka, Mario, Gringeri, Alessandro, Mantovani, Lorenzo, Garrido, Rosario Pérez, Schiavoni, Mario, Villar, Anna, Windyga, Jerzy, European Haemophilia Therapy Standardi-sation Board [EHTSB], Hermans, Cédric, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service d'hématologie, Astermark, Jan, Morado, Martha, Rocino, Angiola, van den Berg, H Marijke, von Depka, Mario, Gringeri, Alessandro, Mantovani, Lorenzo, Garrido, Rosario Pérez, Schiavoni, Mario, Villar, Anna, Windyga, Jerzy, European Haemophilia Therapy Standardi-sation Board [EHTSB], and Hermans, Cédric

Abstract

The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical decisions are generally based on subjective opinions, and purchasers' attention is likely to focus on the costs of treatment. In order to assess the current management of inhibitor patients and use of immune tolerance induction therapy (ITI) in Europe, we performed a survey within a European network of 21 comprehensive care centres from 14 countries (the European Haemophilia Therapy Standardisation Board). The survey identified a total of 381 patients with inhibitors attending the centres, 211 (55.4%) of whom had never been exposed to ITI. Between 1998 and 2003, the centres performed 233 procedures and 114 (48.9%) were successful. The survey demonstrated that dosing, which is the time to start and stop the ITI, the type of concentrate to use and the definition of success varied among the centres. Well-designed trials are warranted to guide decision-making, but in the absence of these studies we have developed consensus guidance for the management of inhibitor patients based on current clinical practice, as identified by the survey, and review of the literature.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results